Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR vs FC in previously untreated CLL
NCT00281918Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2003
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of rituximab in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Roche. Primary endpoint: Progression-free Survival at 66.4 months. Started Jul 2003; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00281918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281918.